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Pancreatic ductal adenocarcinoma (PDAC) is characterised pathologically by a marked desmoplastic stromal reaction that significantly
reduces the sensitivity and specificity of cytogenetic analysis. To identify genetic alterations that reflect the characteristics of the
tumour in vivo, we screened a total of 23 microdissected PDAC tissue samples using array-based comparative genomic hybridisation
(array CGH) with 1Mb resolution. Highly stringent statistical analysis enabled us to define the regions of nonrandom genomic
changes. We detected a total of 41 contiguous regions (43.0Mb) of copy number changes, such as a genetic gain at 7p22.2–p15.1
(26.0Mb) and losses at 17p13.3–p11.2 (13.6Mb), 18q21.2–q22.1 (12.0Mb), 18q22.3–q23 (7.1Mb) and 18q12.3–q21.2 (6.9Mb).
To validate our array CGH results, fluorescence in situ hybridisation was performed using four probes from those regions, showing
that these genetic alterations were observed in 37–68% of a separate sample set of 19 PDAC cases. In particular, deletion of the
SEC11L3 gene (18q21.32) was detected at a very high frequency (13 out of 19 cases; 68%) and in situ RNA hybridisation for this gene
demonstrated a significant correlation between deletion and expression levels. It was further confirmed by reverse transcription–
PCR that SEC11L3 mRNA was downregulated in 16 out of 16 PDAC tissues (100%). In conclusion, the combination of tissue
microdissection and array CGH provided a valid data set that represents in vivo genetic changes in PDAC. Our results raise the
possibility that the SEC11L3 gene may play a role as a tumour suppressor in this disease.
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Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading
cause of cancer-related death in Western countries. Although the
prognosis of patients with many types of cancer has improved
recently due to advances in diagnostic and therapeutic modalities,
the outlook for patients with PDAC still remains dismal with a
median survival of just 6 months from diagnosis and an overall 5-
year survival rate of less than 5% (Warshaw and Fernandez-del
Castillo, 1992; Murr et al, 1994; Jemal et al, 2005). Many previous
studies have attempted to elucidate the molecular mechanisms
underlying pancreatic tumorigenesis, but it is still not fully
understood. Therefore, a better understanding of the genes
involved in tumour growth and progression is necessary for the
development of novel diagnostic and therapeutic strategies that
could improve the outcome of this deadly disease.
Array-based comparative genomic hybridisation (array CGH) is
a powerful technique that has been used to detect DNA copy
number alterations across the entire genome of malignant tumours
(Solinas-Toldo et al, 1997; Pinkel et al, 1998; Pollack et al, 1999;
Albertson et al, 2000; Snijders et al, 2001; Fiegler et al, 2003).
Compared to conventional CGH, the significantly improved
resolution of array CGH permits highly accurate mapping of
DNA copy number changes throughout the genome. In cancer,
genomic alterations contribute to dysregulation of the expression
levels of oncogenes and tumour suppressor genes, the accumula-
tion of which is correlated with tumour progression (Ried et al,
1999). Therefore, array CGH provides a promising starting point
for the identification of novel candidate genes affected by such
genomic imbalances. Several array CGH investigations of PDAC
have already been reported, but all these studies were performed
on cell lines or whole tissue samples (Aguirre et al, 2004;
Heidenblad et al, 2004; Holzmann et al, 2004; Mahlamaki et al,
2004; Bashyam et al, 2005; Gysin et al, 2005; Nowak et al, 2005). In
cell lines, culture-induced genetic adaptation may be induced
during the establishment of cell lines in in vitro conditions. On the
other hand, PDAC tissues are characterised by a desmoplastic
reaction, with neoplastic cells constituting only a small proportion
of the tumour mass. Therefore, cytogenetic analysis using bulk
tissue samples is invariably hampered by contamination with non-
neoplastic cells.
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sThe aim of this study is to identify novel genetic abnormalities
that precisely reflect the characteristics of tumour cells in vivo. For
this purpose, we applied array CGH to 23 microdissected PDAC
tissue samples that consist of purified populations of cancer cells.
Then, a subset of identified genetic alterations was evaluated in an
independent sample set of 19 PDAC cases using fluorescence in
situ hybridisation (FISH) analysis. Finally, in situ RNA hybridisa-
tion (ISH) and reverse transcription–PCR (RT–PCR) were
performed to assess whether the identified genetic alteration could
lead to significant change in transcript level of the gene in
question.
MATERIALS AND METHODS
Tissue samples
A total of 23 fresh-frozen PDAC specimens were obtained
surgically or at autopsy from Yamaguchi University School of
Medicine, Japan, with appropriate ethical approval (Table 1). All
the tissues were confirmed histologically by a pathologist. Tissue
microdissection was performed manually to collect more than 90%
of tumour cells in all the cases as described previously (Harada
et al, 2002a). Briefly, only cancerous regions were microdissected
using a sterile 26-gauge needle from several serial tissue sections
(20mm thickness) under visualisation with an inverted microscope
(Nikon 66906, Tokyo, Japan). DNA was extracted from at least
5000 tumour cells according to the standard protocol. Reference
DNA was obtained from lymphocytes of both healthy male and
female volunteers. In addition, another series of 19 formalin-fixed,
paraffin-embedded tumour sections (4mm thickness) were pro-
vided from Yamaguchi University (n¼10) and Tohoku University
School of Medicine, Japan (n¼9), for FISH and ISH analyses
(Table 1). Owing to the limited accessibility of clinical specimens,
the samples used in array CGH were not available for FISH and
ISH. For RT–PCR, 16 fresh-frozen PDAC tissues and two normal
pancreas tissues were obtained from the Human Biomaterials
Resource Centre, Department of Histopathology, Charing Cross
Table 1 The clinicopathological data of PDAC tissue samples
Sample Age Sex Location
a Histology
b T N M Stage
(A) Microdissected fresh-frozen tissue samples used for array CGH (n¼23)
PC1 66 F P(Ph) mod 3 0 0 II
PC2 66 F P(Pb) well 3 1a 0 III
PC3 66 M P(Ph) mod 3 1b 0 III
PC4 59 F P(Ph) mod 3 1b 0 III
PC5 64 M P(Ph) mod 3 1b 0 III
PC6 47 M P(Ph) mod 4 1b 0 IVa
PC7 66 M P(Ph) mod 4 1b 0 IVa
PC8 69 F P(Ph) poor 4 1b 0 IVa
PC9 73 F P(Ph) mod 4 1b 0 IVa
PC10 56 M P(Pt) mod 4 1b 1 IVb
PC11 76 F P(Ph) mod 4 1b 1 IVb
PC12 63 F P(Pb) mod 4 1b 1 IVb
PC13 78 F P(Pt) mod 4 1b 1 IVb
PC14 68 F P(Ph) mod 4 1b 1 IVb
PC15 65 M P(Pb) mod 4 1b 1 IVb
PC16 65 M P(Ph) mod 4 1b 1 IVb
PC17 60 M P(Ph) mod 4 1b 1 IVb
PC18 76 M P(Ph) mod 4 1b 1 IVb
PC19 54 F P(Pb) poor 4 1b 1 IVb
PC20 72 F P(Pt) mod 4 1b 1 IVb
PC34 60 M LM mod 4 1b 1 IVb
PC35 75 M LM mod 4 1b 1 IVb
PC36 67 F LM mod 4 1b 1 IVb
(B) Formalin-fixed, paraffin-embedded tissue sections used for FISH and ISH (n¼19)
PC37 74 M P(Ph) mod 2 0 0 I
PC38 72 M P(Pt) poor 3 0 0 II
PC39 70 M P(Ph) mod 3 1 0 III
PC40 58 M P(Ph) mod 3 1 0 III
PC41 69 F P(Pb) well 3 1 0 III
PC42 51 M P(Ph) poor 3 1 0 III
PC43 73 M P(Ph) mod 3 1 0 III
PC44 59 M P(Pb) mod 3 1 0 III
PC45 53 F P(Ph) mod 4 1 0 IVa
PC46 53 M P(Pb) mod 4 1 0 IVa
PC47 56 M P(Ph) well 4 1 0 IVa
PC48 57 F P(Ph) mod 3 1 1 IVb
PC49 65 F P(Ph) mod 3 1 1 IVb
PC50 59 M P(Ph) mod 3 1 1 IVb
PC51 61 M P(Ph) mod 4 1 1 IVb
PC52 74 M P(Pb) poor 4 1 1 IVb
PC53 57 F LM mod 3 1 1 IVb
PC54 61 M LM mod 4 1 1 IVb
PC55 74 M LM poor 4 1 1 IVb
aP¼primary lesion; Ph¼head; Pb¼body; Pt¼tail of the pancreas; LM¼liver metastatic lesion.
bmod¼moderately; poor¼poorly differentiated tubular adenocarcinoma.
PDAC¼pancreatic ductal adenocarcinoma; FISH¼fluorescence in situ hybridisation; ISH¼in situ RNA hybridisation.
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sHospital, London, UK, with full ethical approval of the host
institution. The clinicopathological information was not available
for these anonymous samples. Haematoxylin–eosin-stained slides
were examined to ensure a content of 60–80% tumour cells before
use and then, total RNA was extracted directly from homogenised
tissues using TRIZOL (Invitrogen Ltd, Paisley, UK).
CGH arrays and image acquisition
The whole-genome CGH arrays were produced at the Wellcome
Trust Sanger Institute and consist of 3125 BAC/PAC clones that
cover the entire human genome at 1Mb resolution (Fiegler et al,
2003). All the clone details are available on the Ensembl genome
browser (v39, June 2006; http://www.ensembl.org/Homo_sapiens/
index.html).
Array CGH was performed as described previously, with minor
modifications (Fiegler et al, 2003; Hurst et al, 2004). Briefly,
tumour and reference DNAs (300ng) were labelled with Cy5-dCTP
and Cy3-dCTP, respectively. Hybridisation was carried out at 371C
for 36h in a hybridisation chamber (GeneMachines, San Carlos,
CA, USA). After washing the slides, fluorescence intensities were
measured on an Axon 4000B scanner (Axon Instruments Inc.,
Burlingame, CA, USA) and the raw images were analysed using the
GenePix Pro 4.0 software (Axon). Duplicate hybridisations were
performed for each sample to verify the reproducibility of the data
except for one case (PC5). The correlation coefficients were
calculated on the normalised tumour channel and observed to
range from 0.63 to 0.90 (data not shown).
Statistical and data analysis
The CGH arrays were read with the UCSF ‘SPOT’ software to
produce raw text files (Jain et al, 2002). These files were read into R
and normalised (using the loess intensity-dependent method),
using the ‘limma’ package (Smyth, 2005; The R Development Core
Team, 2006); background correction was omitted in this case, as
visual inspection showed it increased the scatter in both the MA
and chromosomal-location plots, and the correlation statistics
were worse with background subtraction, indicative of low levels of
background on the slides being misestimated. The log2-trans-
formed normalised data were then pre-processed to average any
on-slide replicates using the ‘snapCGH’ package from Bioconduc-
tor and segmented into local regions of constant copy number by
circular binary segmentation (Gentleman et al, 2004; Olshen et al,
2004). The sample levels (two replicates for each tumour per clone)
were summarised by means to give tumour-level data (one
measurement per clone for each tumour). These data were then
used in a linear model that estimated the fold change across the
tumours, along with a P-value that the average log2-fold change
between the tumour channel and the normal channel was non-zero
(for both the normalised data and the locally smoothed data – data
not shown for the latter). Clones that had an uncorrected P-value
below 0.001 were considered to be significant candidates.
Two-colour FISH
Four human BAC clones (RP11-403N12, RP11-232C20, RP11-8H2
and RP11-350K6) were purchased from BACPAC Resources
(Oakland, CA, USA) and these DNAs were labelled with Cy3-
dCTP using BioPrime Array CGH Genomic Labeling System
(Invitrogen). Centromeric probes for chromosomes 7 and 18
(CEP7 and 18), labelled with SpectrumGreen, were purchased from
Vysis (Downers Grove, IL, USA). The specificity of all the probes
was confirmed by hybridisation onto Normal Male Metaphase
(Vysis).
Two-colour FISH was performed as described previously (Lu
et al, 1999). DNA copy number was evaluated for each probe by
counting spots in at least 100 nuclei. A ratio was calculated
between the average copy number of the BAC probes and of
corresponding centromeric probes. Based on hybridisation in 10
normal pancreatic tissues (acinar and ductal cells), the threshold of
gain and loss was defined as the ratios of 41.16 (þ2 standard
deviation (s.d.)) and o0.87 ( 2 s.d.), respectively (data not
shown). Our approach was to use normal samples to estimate
overall noise levels: choosing the threshold on the tumour samples
corresponding to a 72 s.d. of the normal samples indicates a
roughly 5% false-positive rate if the tumour samples were
commensurate with diploidy.
In situ RNA hybridisation for SEC11L3
The SEC11L3 probe was amplified by PCR from OriGene clone
TC123085 (OriGene Technologies, Inc., Rockville, MD, USA) that
encodes full-length cDNA of SEC11L3. The primers used to amplify
a 216-bp SEC11L3 product are as follows: forward 50-TTGGATA
TCTTCGGGGACCT-30 and reverse 50-GTCTTCCCGGAAATTTGT
GA-30. The PCR product was cloned into the pCR4-TOPO vector
using the TOPO cloning kit (Invitrogen) to create pCR4-SEC11L3-
ISH. Positive clones were verified by sequence analysis. The pCR4-
SEC11L3-ISH plasmid was linearised with PstI for the sense probe
and NotI for the antisense probe. After removing restriction
endonucleases, riboprobes were synthesised from 1mg of template
DNA and digoxigenin (DIG) were labelled using a DIG RNA
labeling kit (Roche Diagnostics GmbH, Mannheim, Germany). T3
and T7 polymerases were used to synthesise antisense probes and
sense probes, respectively. DIG incorporation of riboprobes was
verified by DOT blot with anti-digoxigenin-AP Fab fragments
(Roche). Antisense and sense riboprobes for SEC11L3 were
hybridised to 19 tissue sections using the Ventana Discovery
System with Ventana Ribomap and Bluemap kits. Expression of
SEC11L3 mRNA in cancer cells was compared to that of non-
neoplastic epithelial cells (ductal, acinar, intestinal and hepatic
cells) on the identical specimen and judged using a 0–2 score
(0¼no staining, 1¼weak intensity, 2¼intensity comparable to
non-neoplastic counterparts).
Reverse transcription–PCR for SEC11L3
cDNAs were synthesised from 1mg of total RNA using an oligo dT
primer and the Multiscribe reverse transcription kit (Applied
Biosystems, Warrington, Cheshire, UK) as instructed by the
manufacturer. Reverse transcription was followed by 30 PCR
cycles (1min of denaturation at 941C, 1min of annealing at 551C
and 1min of extension at 721C). Primers for SEC11L3 are the same
as those designed in ISH. Primers for 18S ribosomal RNA, which
was used as an endogenous control for normalisation, are as
follows: forward 50-CGCCGCTAGAGGTGAAATTC-30 and reverse
50-CATTCTTGGCAAATGCTTTCG-30. Amplified products were
separated on 1% agarose gels and visualised with ethidium
bromide.
RESULTS
Comparison of array CGH profiles in microdissected
tissues and cell lines
A total of 23 microdissected PDAC tissues were analysed by array
CGH. Applying highly stringent statistical conditions (Po0.001),
we could identify the regions of nonrandom genomic changes in
PDAC. Figure 1 shows overall copy number changes for each
chromosome and the entire data set of all clones is available in
Supplementary Table 1 (the raw data set for all the experiments is
shown in Supplementary Table 2). A total of 1015 clones met the
statistical criterion; 17% of clones (508 clones including 698
candidate genes) showed genetic gain and 17% (507 clones
including 1254 genes) showed loss. The array CGH profiles were
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were analysed (Aguirre et al, 2004; Bashyam et al, 2005; Gysin et al,
2005; Nowak et al, 2005). Although they displayed similar
spectrum patterns of genetic alterations overall, we found that
there were apparently different breakpoints in our profiles. Our
data showed several segmented gains on chromosome 2, which
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Figure 1 Summary of overall genome-wide alterations in a total of 23 microdissected PDAC tissues. Genetic gains are shown as green dots and losses as
red dots (Y axis) at each clone position along the chromosome (X axis). Several representative clones with no genetic changes are depicted as black dots.
Square-shaped dots indicate the clones validated by FISH, whereas triangle dots indicate previously identified genes in PDAC. Vertical dotted lines represent
chromosome centromeres.
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shave rarely been observed in cell lines. In contrast, losses of 4q and
13q and gains of 11q and 20q in cell lines were not as frequent as in
our microdissected samples. Next, we focused on individual clones
harbouring the genes that are known to be dysregulated in cell
lines. Increased copy numbers were detected in the regions
including MYC (8q24.21) and NCOA3/AIB1 (20q13.12), while
genetic losses were observed in the regions containing SMAD4
(18q21.1), TP53 (17p13.1), MAP2K4 (17p11.2) and RUNX3
(1p36.11). However, using the rigorous statistical conditions
employed, we identified neither genetic gains of KRAS (12p12.1),
MYB (6q23.3), EGFR (7p11.2) and ERBB2 (17q12) nor losses of
MLH1 (3p22.2), BRCA2 (13q13.1) and CDH1 (16q22.1). (All the
genes cited here are depicted in Figure 1.)
Contiguous regions of nonrandom copy number changes
In addition to numerous localised alterations, we detected a total
of 41 contiguous regions (43.0Mb) of nonrandom genomic
changes (Table 2). For instance, increased copy number was
detected in the 26.0Mb region of 7p22.2–p15.1 that contains 48
known or hypothetical protein-coding genes. We also defined the
regions of genetic gains on 1q, 3q, 5p, 5q, 8q and 12p, which may
represent loci for candidate oncogenes in PDAC. The largest region
of copy number loss was from 17p13.3 to 17p12 (13.6Mb), which
covers a total of 53 candidate genes including TP53 (17p13.1) as
well as MAP2K4 (17p11.2). We delineated three contiguous regions
of genomic loss on 18q, which is known to be a site of frequent
deletions in PDAC, 18q21.2–q22.1 (12.0Mb), 18q22.3–q23
(7.1Mb) and 18q12.3–q21.2 (6.9Mb). The region of 18q21.2–
q22.1 harbours 16 candidate genes in addition to SMAD4 (18q21.1)
that is one of the most recurrently inactivated tumour suppressor
genes in PDAC. The region of 18q12.3–q21.2 contains a total of 23
putative target genes, whereas seven genes are included in the
7.1Mb region of 18q22.3–q23. Interestingly, the clone encom-
passing DCC (18q21.2) has shown an apparent discontinuity
between two broad regions of genetic loss (18q12.3–q21.2 and
18q21.2–q22.1) in our 23 microdissected PDAC sample set
(Figure 1).
Verification of genetic changes by two-colour FISH
To investigate prospectively whether the identified genetic
abnormalities are prevalent in PDAC, interphase FISH analysis
was performed using an independent sample set (Figure 2).
Previous cytogenetic studies have shown that chromosome arms
7p and 18q may include oncogenes and tumour suppressor genes
that play a critical role in pancreatic carcinogenesis (Griffin et al,
1995; Hahn et al, 1995; Fukushige et al, 1997, 1998; Mahlamaki
et al, 1997; Schleger et al, 2000; Harada et al, 2002a; Iacobuzio-
Donahue et al, 2004). Therefore, we prioritised three regions
(7p22.3–p15.1, 18q12.3–q21.2 and 18q21.2–q22.1) of nonrandom
copy number changes detected in array CGH and a subset of four
BAC clones (RP11-403N12 at 7p21.1, RP11-232C20 at 7p15.2,
RP11-8H2 at 18q21.1 and RP11-350K6 at 18q21.32) were selected
from those regions (Table 3). As shown in Table 4, deletion in the
locus encompassing SEC11L3 (18q21.32) was observed to be the
most recurrent alteration (13 out of 19 samples; 68%) (Figure 2B).
The region 18q21.1 defined by RP11-8H2 was deleted in 11 out of
19 cases (58%) and contains three known candidate genes:
ATP5A1, PSTPIP2 and CCDC5. RP11-403N12 including BCMP11
(7p21.1) showed an increased copy number in 10 out of 19 cases
(53%) (Figure 2C), whereas gain of the region at RP11-232C20
containing SCAP2 (7p15.2) was demonstrated in seven out of 19
cases (37%) (Figure 2D).
SEC11L3 mRNA downregulation detected by ISH and
RT–PCR
Subsequently, the SEC11L3 mRNA level was evaluated by ISH
(Figure 3). Firstly, we tested several different types of normal
epithelial cells from the pancreas, intestine and liver. Normal
pancreatic tissues showed strong mRNA expression of SEC11L3 in
both ductal and acinar cells (score 2), whereas there was weak
expression in islet cells (score 1). Strong expression was also
observed in normal intestinal and hepatic cells (score 2). Of 19
PDAC cases, SEC11L3 mRNA was downregulated (score 0–1) in 11
cases (58%), whereas it was unchanged (score 2) in eight cases
Table 2 Contiguous regions (43.0Mb) of chromosomal changes in a total of 23 microdissected PDAC tissues
Locus Start (bp) End (bp) Size (Mb) Mean log2 Locus Start (bp) End (bp) Size (Mb) Mean log2
1q24.1–q25.1 163809021 173127283 9.3 0.235 1p35.1–p34.3 34152076 38379441 4.2  0.232
1q25.2–q25.3 177942453 181046133 3.0 0.208 4p16.2–p16.1 5094062 8313477 3.2  0.216
1q31.1–q31.3 187406225 195710013 8.3 0.255 6p21.32–p21.31 32031967 34013145 4.0  0.219
1q41 215371867 219919554 4.5 0.242 6q21 108154127 112486834 4.3  0.181
1q42.2–q43 231700764 241495322 9.8 0.253 6q25.2–q25.3 155289734 158440778 3.2  0.204
2p16.1–p14 60927185 64676357 4.8 0.171 8p22–p21.3 17784184 21872595 4.1  0.264
2q22.2–q22.3 143499638 146775971 3.3 0.168 9p24.3–p24.1 190 6659690 6.7  0.228
2q32.1 185140061 188357186 3.2 0.161 9p22.1–p21.3 19310506 23557472 4.2  0.256
2q32.3 192914919 196752218 3.8 0.146 9q22.31–q22.33 94281893 100889311 6.6  0.171
3q26.1 163532324 167501265 4.0 0.237 9q33.3–q34.11 126127921 129390787 3.3  0.216
5p15.31–p15.2 7449057 10495937 3.0 0.165 9q34.13–q34.3 133982008 137333442 3.4  0.226
5p14.3–p14.1 20429524 28918008 8.5 0.232 17p13.3–p12 800495 14360892 13.6  0.252
5q11.1–q11.2 50061482 54725678 4.7 0.174 18q12.3–q21.2 41216566 48119508 6.9  0.350
5q12.2–q13.1 63325516 66888015 3.6 0.149 18q21.2–q22.1 49795841 61752947 12.0  0.252
5q14.1–q14.3 80075105 86472400 6.4 0.168 18q22.3–q23 68809458 75940259 7.1  0.294
5q14.3 87676680 90964362 3.3 0.170 21q21.3–q22.11 29627040 34602938 5.0  0.182
7p22.2–p15.1 2607390 28603446 26.0 0.207 22q11.22–q12.1 21400636 25896652 4.5  0.205
7p14.1 38185228 41345287 3.2 0.170 22q12.2-q12.3 28379384 31627100 3.2  0.180
7q21.11 79539131 83414012 3.9 0.219
8q21.11–q21.13 77234275 81648851 4.4 0.225
8q21.13–q21.3 82640038 89400934 6.8 0.271
8q24.11–q24.13 118297084 123697997 5.4 0.254
12p12.3–p12.1 19403674 23784534 4.4 0.268
PDAC¼pancreatic ductal adenocarcinoma.
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sTable 3 Contiguous regions of nonrandom copy number changes on 7p and 18q
BAC Region Genes included
a Overall results
Clone ID
b Cytoband Start (bp) End (bp) Size (bp) Size (Mb)
c No Plausible candidates Mean log2 Fold changes P-value
RP11-106E3 7p22.2 2607390 2657138 49749 26.0 2 IQCE 0.134 1.098 0.000242
RP11-172O13 7p22.1 5704716 5847079 142364 1 TRIAD3 0.182 1.135 5.25E-06
RP1-42M2 7p22.1 5969700 6049710 80011 7 PMS2, EIF2AK1 0.165 1.121 0.000272
RP4-810E6 7p22.1 6049510 6202437 152928 6 PSCD3, EIF2AK1 0.220 1.164 1.23E-06
RP11-425P5 7p22.1 6233987 6446613 212627 4 RAC1, PSCD3 0.144 1.105 0.000254
RP4-733B9 7p22.1-p21.3 7176436 7292189 115754 1 C1GALT1 0.189 1.140 4.92E-07
RP11-505D17 7p21.3 7947759 8125919 178161 2 GLCCI1, ICA1 0.231 1.174 1.07E-08
RP11-304A10 7p21.3 8950512 9040173 89662 0 0.144 1.105 0.000274
RP5-959C21 7p21.3 9924891 10064840 139950 0 0.143 1.104 6.08E-06
RP11-352E12 7p21.3 10064640 10151963 87324 0 0.190 1.141 2.08E-06
RP11-392P1 7p21.3 10372373 10429780 57408 0 0.207 1.155 3.66E-08
RP11-502P9 7p21.3 11782368 11938707 156340 0 0.254 1.192 5.32E-09
RP5-1100A7 7p21.3 12725574 12827381 101808 0 0.226 1.170 9.02E-09
RP11-195L14 7p21.3 12951352 13077542 126191 0 0.242 1.183 1.45E-08
RP4-685A2 7p21.2 13887063 13996422 109360 1 ETV1 0.278 1.213 5.64E-10
RP11-512E16 7p21.2 14128072 14279388 151317 1 DGKB 0.262 1.199 1.75E-09
RP11-196O16 7p21.1 16023294 16205465 182172 2 0.182 1.135 8.23E-07
RP11-403N12 7p21.1 16865247 17055918 190672 1 BCMP11 0.239 1.181 2.76E-08
RP11-323K15 7p21.1 17781327 17929240 147914 1 SNX13 0.109 1.079 9.16E-05
RP11-71F18 7p21.1-p15.3 19406242 19580569 174328 0 0.147 1.107 8.00E-06
RP11-486P11 7p15.3 20042179 20150597 108419 1 7A5 0.317 1.246 1.30E-11
RP4-701O19 7p15.3 20884182 20950414 66233 0 0.190 1.140 4.72E-05
RP11-211J15 7p15.3 21173901 21257598 83698 2 0.183 1.135 2.43E-07
RP11-445O1 7p15.3 21588234 21669042 80809 1 DNAH11 0.210 1.157 9.97E-08
RP11-451F11 7p15.3 23714553 23804532 89980 1 STK31 0.346 1.271 1.43E-11
RP11-343P21 7p15.3 24511504 24521807 10304 0 0.226 1.169 3.17E-08
RP11-99O17 7p15.2 25824267 25925677 101411 0 0.225 1.169 2.79E-07
RP11-232C20 7p15.2 26765660 26911371 145712 1 SCAP2 0.275 1.210 1.80E-10
RP4-781A18 7p15.2-p15.1 27976171 28166812 190642 2 tcag7.981 0.181 1.133 1.83E-06
RP4-596O9 7p15.1 28459769 28603446 143678 1 CREB5 0.175 1.129 8.62E-06
RP11-463D17 18q12.3 41216566 41408713 192148 6.9 0  0.439  1.356 1.00E-11
RP11-8H2 18q21.1 41851567 41984947 133381 5 ATP5A1, CCDC5, PSTPIP2  0.249  1.189 1.50E-07
RP11-313C14 18q21.1 42350383 42350954 572 1 LOXHD1  0.471  1.386 5.75E-13
RP11-71F23 18q21.1 43069131 43274185 205055 0  0.451  1.367 2.87E-11
RP11-46D1 18q21.1 44393176 44552924 159749 1 KIAA0427  0.264  1.201 1.85E-05
RP11-141E12 18q21.1 45025819 45187979 162161 1 DYM  0.150  1.109 0.000150
RP11-419L16 18q21.1-q21.2 46310160 46473840 163681 1 MAPK4  0.378  1.300 1.02E-06
RP11-76E22 18q21.2 46462730 46633371 170642 2 MRO  0.393  1.313 3.94E-10
RP11-729G3 18q21.2 46732284 46888494 156211 4 SMAD4, ELAC1  0.389  1.309 2.67E-08
RP11-1E21 18q21.2 47274828 47443303 168476 2  0.322  1.250 2.22E-08
RP11-25O3 18q21.2 47958320 48119508 161189 0  0.346  1.271 1.64E-06
RP11-116K4 18q21.2 49795841 49971830 175990 12.0 1 MBD2  0.331  1.258 6.44E-08
RP11-99A1 18q21.2 50563151 50702093 138943 1 RAB27B  0.374  1.296 4.86E-08
RP11-397A16 18q21.2 51445553 51648118 202566 1  0.263  1.200 1.58E-07
RP11-383D22 18q21.31 52656265 52867730 211466 2 WDR7  0.179  1.132 0.000196
RP11-35G9 18q21.31 53447744 53561700 113957 4 ATP8B1  0.195  1.145 1.99E-06
RP11-61J14 18q21.32 54567090 54747580 180491 6 ZNF532, MALT1  0.223  1.167 3.87E-07
RP11-350K6 18q21.32 54867252 55027999 160748 1 SEC11L3  0.289  1.222 5.58E-09
RP11-396N11 18q21.32 56063594 56151592 87999 0  0.233  1.176 7.74E-08
RP11-520K18 18q21.32 56874822 57034w619 159798 0  0.230  1.173 1.22E-06
RP11-13L22 18q21.33 58408978 58578530 169553 3 PHLPP  0.320  1.248 3.63E-11
RP11-215A20 18q21.33 58572412 58756503 184092 2 PHLPP  0.198  1.147 1.24E-05
RP11-233O10 18q22.1 59886252 59971318 85067 1 C18orf20  0.250  1.189 2.21E-10
RP11-389J22 18q22.1 61594898 61752947 158050 1 CDH7  0.189  1.140 8.76E-07
RP11-169F17 18q22.3 68809458 69000813 191356 7.1 0  0.329  1.256 4.02E-10
RP11-25L3 18q22.3 69588036 69755177 167142 0  0.236  1.177 8.63E-08
RP11-556L15 18q22.3 70753437 70931323 177887 1 ZNF407  0.348  1.272 3.55E-09
RP11-396D4 18q22.3–q23 71168342 71337306 168965 1  0.261  1.198 1.51E-07
RP11-234N1 18q23 72266630 72448118 181489 2 ZNF516  0.373  1.295 3.41E-11
RP11-118I2 18q23 73613846 73764173 150328 0  0.275  1.210 1.20E-06
RP11-16L7 18q23 73908671 74017409 108739 0  0.271  1.206 2.94E-12
RP11-563B11 18q23 74707626 74870951 163326 1 SALL3  0.294  1.226 3.81E-07
RP11-154H12 18q23 75586355 75701258 114904 2 CTDP1  0.321  1.249 1.20E-08
CTC-964M9 18q23 75939424 75940259 836 0  0.230  1.173 9.86E-06
aThe four clones that were used in FISH analysis are outlined in bold.
bThe size of the contiguous region.
cThe number of genes included in each clone and examples of candidate
genes contained within each clone. All the details are shown in Supplementary Table 1.
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s(42%) (Table 4). All 11 cases with downregulated SEC11L3
demonstrated genetic losses by FISH. Despite decreased copy
numbers, SEC11L3 was expressed in two samples (PC46 and
PC51). A significant correlation between deletion and expression
levels was found (P¼0.001, Fisher’s exact test), indicating that the
mRNA level of this gene was highly dependent on its DNA copy
number.
RT–PCR was performed further to confirm downregulated
mRNA of SEC11L3 in PDAC. Figure 4 shows SEC11L3 expression
in normal pancreas and PDAC tissue samples. Compared to two
normal pancreas tissues, SEC11L3 was found to be downregulated
in 16 out of 16 PDAC samples (100%). In particular, the SEC11L3
transcript was virtually almost absent in four PDAC tissues (25%;
lane 5, 6, 7 and 15).
DISCUSSION
It is well known that a strong desmoplastic reaction is a typical
feature of PDAC tissues. A dense stromal component, which
occupies larger parts of the tumour mass, significantly reduces the
sensitivity and specificity of cytogenetic analysis. Tissue micro-
dissection is laborious, but the practical method available to enrich
the tumour cell population in clinical specimens. In the present
study, we first identified genomic abnormalities that represent the
characteristics of tumour cells in vivo by combining CGH arrays
with tissue microdissection. This approach led to more precise
definition of chromosomal breakpoints in a panel of 23 PDAC
tissue samples. To identify nonrandom genomic changes in PDAC,
we applied a P-value rather than a fixed cutoff value because
we found that concomitant lack of power in dichotomising the
data at an early stage in the analysis provided poor resolution
with which to distinguish between clones. Taking a statistical
threshold approach allows us to take account of different clones’
differing variance across samples that a fixed fold-change
approach does not.
We compared the CGH profiles to the previously published cell
line data (Karhu et al, 2006). Despite overall similar spectrum
patterns, there were clear differences between both profiles. It is
important to take into account that the resolution of CGH arrays
used and the type of statistical analysis employed vary widely
between the reports. However, our results indicated that some
recurrent genetic alterations, such as losses of 4q and 13q and
gains of 11q and 20q, seem to be relatively unique to cell lines,
implying that these genetic changes may have been artificially
acquired through the establishment of cell lines or in the course of
culturing. In addition, our data did not demonstrate significant
copy number changes of some known genes, such as KRAS,
ERBB2, MLH1 and CDH1. This is probably due to the fact that
intragenic mutation or promoter methylation is more likely to
occur in these genes (Lemoine et al, 1992; Scarpa et al, 1994;
Rozenblum et al, 1997; Ueki et al, 2000). Alternatively, this
discrepancy could be explained by the intratumoral heterogeneity
that is characteristically observed in PDAC cells in vitro as well as
in vivo, or may reflect the differences of the geographic origin of
the tumours used in this study (a total of 42 Japanese samples were
Table 4 The results of FISH and ISH analyses
a
Clone ID/candidate RP11-403N12/BCMP11 RP11-232C20/SCAP2 RP11-8H2/ATP5A1
RP11-350K6/SEC11L3
Analysis FISH FISH FISH FISH ISH
PC37 1.05 0.99 0.71 0.83 1
PC38 1.02 1.12 0.94 0.94 2
PC39 0.98 1.09 1.05 0.77 0
PC40 1.01 1.30 0.95 0.57 1
PC41 1.13 0.93 0.20 0.46 0
PC42 1.28 1.18 0.56 0.91 2
PC43 1.23 0.94 0.91 0.71 1
PC44 1.35 1.52 0.66 0.94 2
PC45 1.01 1.01 0.63 0.71 1
PC46 1.06 1.13 0.94 0.86 2
PC47 0.98 1.03 0.74 0.36 0
PC48 1.59 0.94 0.90 0.51 0
PC49 1.17 1.24 0.58 1.04 2
PC50 1.01 1.03 0.94 0.63 0
PC51 1.24 1.26 0.64 0.82 2
PC52 1.25 0.97 0.85 1.11 2
PC53 1.49 1.14 0.71 0.70 1
PC54 1.39 1.50 0.51 0.52 0
PC55 1.41 1.50 0.95 1.08 2
Frequency (%) 10/19 (53%) 7/19 (37%) 11/19 (58%) 13/19 (68%) 11/19 (58%)
aSignificant differences are outlined in bold. FISH¼fluorescence in situ hybridisation; ISH¼in situ RNA hybridisation.
AB
CD
Figure 2 Four representative images in FISH analysis. Target BAC DNA
probes were labelled with Cy3-dCTP (red), while centromeric probes
were labelled with SpectrumGreen. DNA copy number was evaluated for
each probe by counting spots in at least 100 nuclei. (A) No copy number
change of BCMP11 in PC40. (B) Genetic loss of SEC11L3 in PC48. (C)
Genetic gains of BCMP11 in PC44 and (D)o fSCAP2 in PC49.
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Gorunova et al, 1998; Harada et al, 2002b). Similarly, deletion
of the DCC gene was not recurrent in our sample set. However,
a larger scale of study using much higher-resolution genome-
wide microarrays (tiling-path CGH arrays or single nucleotide
polymorphism arrays) is required to conclude whether this
genetic alteration is critically involved in the pathogenesis of
PDAC.
As our array CGH profiles revealed that the regions of 7p22.2–
p15.1, 18q12.3–q21.2 and 18q21.2–q22.1 are nonrandomly altered,
four clones from those regions were validated by FISH experi-
ments. The results showed that genetic alterations for these clones
were observed in 37–68% of tumours in a separate sample set,
supporting the validity of our CGH results. Moreover, copy
number changes of those four clones were detected in 18 out of 19
PDAC cases (95%), implying the potential clinical applicability.
Among the candidate genes verified by FISH, BCMP11 is newly
detected in PDAC, although Fletcher et al (2003) demonstrated
that mRNA and protein of this gene were overexpressed in
oestrogen receptor-positive breast cancer. This gene lies adjacent
to the AGR2 gene (7p21.1) and both genes are classified as
members of the same family (AGR family) due to highly similar
(approximately 70%) protein sequences. Interestingly, several gene
expression analyses have shown that AGR2 is upregulated in the
majority of PDACs as well as pancreatic intraepithelial neoplasia
(PanIN) lesions (Crnogorac-Jurcevic et al, 2003; Iacobuzio-
Donahue et al, 2003a; Iacobuzio-Donahue et al, 2003b; Missiaglia
et al, 2004; Buchholz et al, 2005). Taken together, BCMP11 is also
likely to be involved in the development of PDAC. On the other
hand, SCAP2 was first described in a recently published report,
ABC
D EF
G HI
Figure 3 SEC11L3 mRNA expression in non-neoplastic epithelial cells and PDAC cells, as determined by ISH. (A) Strong expression (score 2) in both
ductal (white arrows) and acinar cells of non-neoplastic pancreas. (B) ISH conducted with a sense SEC11L3 riboprobe, used as a negative control. (C–E). No
expression (score 0) in PDAC cells (black arrows), but weak expression (score 1) in non-neoplastic islet cells (black arrow heads) (PC41 and 47) (F). Weak
expression (score 1) of PDAC cells in PC43 and (G) strong intensity of expression (score 2) of PDAC cells in PC44. (H) Lower level of expression (score 1;
PC53) and (I) similar intensity of expression (score 2; PC55) in metastatic PDAC cells (black arrows) compared to non-neoplastic hepatic cells (asterisk).
SEC11L3
18s rRNA
123456789 1 0 1 1 1 2 1 3 1 4 1 5 1 6 1 7 1 8 1 9
Figure 4 mRNA expression of SEC11L3 in normal pancreas and PDAC tissues, as determined by RT-PCR. 18S ribosomal RNA was used as an internal
standard. Samples were run in the following order: lane 1–2, normal pancreas; lane 3–18, PDACs; lane 19, negative control. SEC11L3 expression was found
to be present in normal pancreas, while it was decreased in 16 out of 16 PDAC tissues (100%).
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sshowing that mRNA of this gene is frequently overexpressed in
PanIN lesions (Buchholz et al, 2005). The protein encoded by this
gene belongs to the src family of kinases. Takahashi et al (2003)
demonstrated that SCAP2 functions as a downstream target of
c-Src under various stress conditions (UV light, tumour necrosis
factor-a and osmotic stress). Therefore, SCAP2 also seems to work
as a cell-signalling molecule in cancer cells. However, the
biological function and putative role of these two genes have not
been investigated in cancer.
Remarkably, SEC11L3 was deleted in approximately 70% of
tumours and its expression level was significantly correlated with
its DNA copy number. Despite the high frequency of this genetic
abnormality, this gene has not been described in any type of
cancer. Previous cytogenetic analyses have revealed a frequent
deletion of 18q in PDAC, but neither the chromosomal breakpoints
nor the candidate genes included could be clearly identified due to
technical limitations of the technology employed (Griffin et al,
1995; Hahn et al, 1995; Fukushige et al, 1997, 1998; Mahlamaki
et al, 1997; Hoglund et al, 1998; Schleger et al, 2000; Harada et al,
2002a; Iacobuzio-Donahue et al, 2004). SMAD4 (18q21.1) has been
reported to be deleted or inactivated in about 50% of PDACs and,
therefore, it is considered to be one of the most likely candidate
tumour suppressor genes at this locus (Hahn et al, 1996;
Rozenblum et al, 1997). However, we propose that SEC11L3
(18q21.32) could be an equally promising candidate gene on 18q
because the significance of genetic loss of this gene is comparable
to that of the SMAD4 gene. In addition, both ISH and RT–PCR
independently confirmed that SEC11L3 mRNA is downregulated
in PDAC tissues at a high frequency (53% and 100%,
respectively), suggesting that dysregulation of this gene is
likely to be associated with the development of PDAC. Little is
known about the biological role of this gene, although it belongs to
the peptidase S26B family and functions as part of the signal
peptidase complex.
In summary, we could successfully identify genetic alterations
that reflect the intrinsic characteristics of PDAC cells in vivo by
combining array CGH with tissue microdissection. These results
provided a valid data set to search for novel candidate genes
involved in pancreatic carcinogenesis. The specificity of our array
CGH results was confirmed by interphase FISH in an independent
sample set. Among the identified candidates, we are particularly
interested in the SEC11L3 gene that is located on 18q21.32. FISH
and ISH analyses for this gene demonstrated a significant
correlation between genetic deletion and the corresponding mRNA
downregulation, raising the possibility that the SEC11L3 gene may
play a putative role as a tumour suppressor. For these reasons, we
propose that SEC11L3 should be considered as a potential marker
gene for the molecular diagnosis of PDAC and a possible candidate
target for therapeutic intervention.
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